How Nemifitide diTFA can Save You Time, Stress, and Money.
MI-CP151 was a period 1b randomised, double-blind, placebo managed, dose-escalation, multicentre examine to evaluate several intravenous doses of sifalimumab, in adult individuals with dermatomyositis or polymyositis (NCT00533091). Key demo targets have been To guage the safety and tolerability of sifalimumab in dermatomyositis or polymyositis suff